Aimmune Therapeutics (NASDAQ:AIMT) Earns News Impact Score of 0.10
News headlines about Aimmune Therapeutics (NASDAQ:AIMT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aimmune Therapeutics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.762852336096 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s rankings:
- Critical Comparison: Aimmune Therapeutics (NASDAQ:AIMT) versus AbbVie (ABBV) (americanbankingnews.com)
- Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) to Post -$0.64 Earnings Per Share (americanbankingnews.com)
- Aimmune Therapeutics, Inc. (AIMT) to Release Earnings on Tuesday (americanbankingnews.com)
- Susan E. Barrowcliffe Sells 500 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock (americanbankingnews.com)
Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at 21.52 on Monday. Aimmune Therapeutics has a one year low of $12.05 and a one year high of $27.31. The stock’s market capitalization is $1.08 billion. The firm has a 50 day moving average price of $20.56 and a 200 day moving average price of $19.90.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.05. Analysts predict that Aimmune Therapeutics will post ($2.66) earnings per share for the current fiscal year.
AIMT has been the subject of several research reports. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Finally, Wedbush reiterated an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $33.00.
TRADEMARK VIOLATION WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/aimmune-therapeutics-nasdaqaimt-earns-news-impact-score-of-0-10.html.
In related news, insider Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eric Bjerkholt bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The stock was bought at an average price of $19.84 per share, with a total value of $99,200.00. Following the completion of the acquisition, the chief financial officer now owns 5,000 shares of the company’s stock, valued at approximately $99,200. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 189,070 shares of company stock valued at $3,954,182. Company insiders own 24.56% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.